A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease

AIDS

Volumn 12, Issue 12, 1998, Pages 1495-1502

  Cohen, Calvin ^a   Revicki, Dennis A ^b   Nabulsi, Azmi ^c   Sarocco, Phillip W ^c   Jiang, Ping ^c  

^a Comm Res Initiative of New England ^*  (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Combination antiretroviral therapy; HIV disease; Quality of life assessment; Randomized clinical trial; Ritonavir

Indexed keywords

CD4 ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DIARRHEA; ENERGY; FATIGUE; FEMALE; HEALTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RITONAVIR; TREATMENT OUTCOME;

EID: 0032552144     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199812000-00012     Document Type: Article

References (28)

1. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
2. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
3. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine and zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
4. Saravolatz LD, Windslow DL, Collins C, et al.: Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1099-1106.
5. Danner SA, Carr A, Leonard JM, et al.: A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1996, 333:1528-1533.
6. Markowitz M, Saag M, Powderly WC, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1996, 333:1534-1539.
7. Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996:334: 1011-1017.
8. Wu AW, Rubin HR, Mathews WC, et al.: Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection. J Acquir Immune Defic Syndr 1993, 6:452-458.
9. Lenderking WR, Gelber RD, Cotton DJ, et al.: Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994, 330:738-743.
10. Stanton DL, Wu AW, Moore RD, et al.: Functional status of persons with HIV infection in an ambulatory setting. J Acquir Immune Defic Syndr 1994, 7:1050-1056.
11. Kempf DJ, Marsh KC, Denissen JF, et al.: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995, 92:2484-2488.
12. Kelleher AD, Carr A, Zaunders I, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
13. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Prolongation of life and prevention of AIDS complications in a randomized placebo-controlled clinical trial of ritonavir in patients with advanced HIV disease. Lancet 1998, 351:543-549.
14. Testa MA, Lenderking WR, Fischer L, et al.: Effects of combination therapy with saquinavir, zidovudine, and zalcitabine on quality of life. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuB542].
15. Wu AW, Rubin HR, Mathews WC, et al.: A health status questionnaire using 30 items from the Medical Outcomes Study: preliminary validation in persons with early HIV infection. Med Care 1991, 29:786-798.
16. Cleary PD, Fowler FJ, Weissman J, et al.: Health-related quality of life in persons with AIDS. Med Care 1993, 31:569-580.
17. Testa MA, Lenderking WR: Quality of life considerations in clinical trials of persons with HIV infection. In AIDS Clinical Trials. Edited by Finkelstein D, Schoenfeld D. New York: Wiley-Liss; 1995:213-241.
18. Revicki DA, Wu AW, Murray M: Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care 1995, 33:AS173-AS182.
19. Burgess A, Catalan J, Deyer M, et al.: The reliability and validity of two HIV-specific health-related quality of life measures. AIDS 1993, 7:1001-1008.
20. Wu AW, Revicki DA, Jacobson D, Malitz FE: Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997, 6:481-493.
21. Revicki DA, Sorensen S, Wu AW: Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998, 36:126-137.
22. Lubeck DP, Fries JF: Changes in quality of life among persons with HIV infection. Qual Life Res 1992, 1:359-366.
23. Lubeck DP, Fries JF: Health status among persons infected with human immunodeficiency virus: a community-based study. Med Care 1993, 31:269-276.
24. Mathez D, DeTruchis P, Gorin I, et al.: A triple combination of ritonavir + AZT + DDC as a first line treatment of patients with AIDS. XI International Congress on AIDS. Vancouver, July 1996 [abstract MoB175].
25. Markowitz M, Cao Y, Hurley A, et al.: Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1. XI International Congress on AIDS. Vancouver, July 1996 [abstract THB933].
26. Wu AW, Jacobson D, Grant D, Scott-Lennox J: Quality of life scores predict clinical trial attrition and mortality. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract 31:298].
27. Nabulsi A, Sarocco P, Revicki D, et al.: The use of EuroQol quality of life instruments in AIDS: results from two clinical trials [abstract]. AIDS 1996, 10 (suppl 2):S32.
28. Cohen CJ, Sun E, Cameron W, et al.: Ritonavir-saquinavir combination treatment in HIV-infection patients. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, September 1996 [abstract LB7b].